Semax Peptide: BDNF, Neuroplasticity and Brain Recovery Research
The brain's response to injury involves more than the survival of individual neurons. Following a stroke, neural networks undergo changes in inflammatory signalling, cellular metabolism and neuroplasticity. Brain-derived neurotrophic factor (BDNF) is one of the molecules studied in this process.
Semax is a synthetic peptide investigated for effects on BDNF-related pathways, nerve growth factor (NGF) and gene expression during experimental cerebral ischemia. A small body of human research has also examined Semax during stroke rehabilitation.
The distinction is important: a change in neurotrophic signalling in rat brain tissue is not automatically evidence of improved memory or neurological recovery in humans.
What Is Semax?
Semax is a seven-amino-acid synthetic peptide derived from an adrenocorticotropic hormone (ACTH) fragment. Its sequence is Met-Glu-His-Phe-Pro-Gly-Pro, also written MEHFPGP. It contains the ACTH(4–7) sequence followed by Pro-Gly-Pro.
Although developed from an ACTH-related fragment, Semax has principally been investigated for neurological signalling rather than conventional adrenal hormone activity.
Characteristic | Semax |
Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) |
Peptide length | Seven amino acids |
Research areas | BDNF, NGF, cerebral ischemia and neuronal stress |
Human evidence | Small regional stroke-rehabilitation studies |
Canadian authorization | No Health Canada-approved therapeutic indication |
How Does Semax Affect BDNF?
BDNF is a neurotrophin involved in neuronal survival, synaptic plasticity and the adaptation of neural circuits. Much of its activity is mediated through the TrkB receptor. This makes BDNF relevant to research on learning and recovery after neurological injury, but an increase in BDNF-related measurements does not automatically imply better cognitive performance.
What the Rat Ischemia Experiment Found
Dmitrieva and colleagues examined neurotrophin and receptor gene expression in rat brains after permanent middle cerebral artery occlusion, an experimental model of ischemic stroke. The investigators measured transcription at three, 24 and 72 hours after the injury.
At 3 hours, Semax increased Bdnf, TrkC and TrkA transcription.
At 24 hours, increased Nt-3 and Ngf transcription was reported.
At 72 hours, increased Ngf transcription persisted in the examined rat tissue.
The findings indicate time-dependent changes in neurotrophic gene expression in injured rat cortex. They are not measurements of human memory or brain recovery. Read the original study.
Semax, NGF and the Timing of Recovery
Nerve growth factor (NGF) supports several aspects of neuronal maintenance and signalling, including activity through TrkA and p75NTR receptors. In the rat experiment, NGF-related transcription changed at later time points than some BDNF-related responses.
This suggests a complex, time-dependent response rather than one uniform increase in all neurotrophic factors. It also creates a research question about how early and later signalling changes may contribute differently to the response after ischemic injury.
What About Inflammation and Cellular Stress?
A 2021 study by Sudarkina and colleagues examined Semax in rats subjected to transient cerebral ischemia followed by reperfusion. The investigators measured proteins associated with inflammation, cellular stress and neuroplasticity, including MMP-9, c-Fos, JNK and CREB.
At 24 hours after ischemia, the study reported increased active CREB in selected subcortical structures, decreased MMP-9 and c-Fos in adjacent frontoparietal cortex, and decreased active JNK in the examined tissues.
These are relevant molecular findings. MMP-9 participates in extracellular matrix remodeling; JNK is associated with stress-response signalling; CREB regulates transcription involved in neuronal adaptation. However, changes in these markers alone do not establish prevention of human stroke disability.
The experiments involved rats, not patients. Read the 2021 molecular study.
What Have Human Studies Found?
A 2018 study examined 110 people recovering from ischemic stroke, including 43 men and 67 women. The researchers compared earlier and later rehabilitation groups, subdivided according to whether they received Semax. Plasma BDNF, motor performance and Barthel Index scores were measured.
The authors reported higher plasma BDNF concentrations in Semax-treated groups and favourable associations with selected measures of functional recovery. They also found that the timing of rehabilitation influenced some of the observed relationships.
These findings provide preliminary human evidence, but the published study does not offer the certainty of a large, independently replicated, double-blind multinational trial. Moreover, plasma BDNF is an indirect measurement; higher circulating BDNF does not necessarily establish increased signalling within a particular brain region.
The correct conclusion is that Semax deserves further clinical investigation, not that its effects on stroke recovery are definitively established. Read the 110-patient study.
Does Semax Improve Memory or Concentration?
Semax is sometimes described as a cognition-enhancing peptide. That proposed application draws partly on its experimental effects on neurotrophic pathways. However, the evidence discussed here primarily involves injured rat brains and a small study of patients recovering from stroke.
Those populations differ substantially from healthy adults. The available findings do not establish reliable improvements in memory, attention or executive function in healthy people.
Semax vs Selank: Different Research Questions
Both are synthetic heptapeptides, but they are derived from different parent molecules and have been investigated in different experimental settings.
Research focus | Semax | Selank |
Structural origin | ACTH-derived | Tuftsin-derived |
Main emphasis | Neurotrophins and neuronal stress | Anxiety-related neurotransmission |
Frequently studied pathways | BDNF, NGF, CREB | GABA-related signalling |
Established cognitive enhancement | Not established | Not established |
These differences reflect research emphasis; they do not prove that either peptide is clinically superior. Kelden's existing migraine article discusses both compounds within the wider context of neurological research.
How Strong Is the Evidence?
Question | Current evidence |
BDNF and NGF transcription | Changes reported in rat cerebral ischemia models |
Inflammation and stress proteins | Alterations reported in rat brain tissue |
Stroke rehabilitation | Preliminary findings from a small human comparative study |
Memory in healthy adults | Reliable benefit not established |
Long-term human safety | Not adequately characterized |
The detailed molecular mechanisms are supported mainly by preclinical experiments. The human rehabilitation findings warrant further study, but they do not support broad claims about cognitive enhancement or reversal of neurological disease.
Semax Research in Canada
Semax is not authorized by Health Canada as a treatment for stroke, cognitive impairment or other neurological conditions. Health Canada identified Semax in a 2025 advisory concerning unauthorized injectable peptide products.
For laboratories and researchers in Vancouver, British Columbia and elsewhere in Canada, evaluating a published Semax study begins with identifying the exact molecule, the experimental model and what was measured. Analytical purity by itself is not evidence of clinical effectiveness.
For the molecular description of Semax research material, see Kelden's Semax research page. Batch-associated documentation is available on the Lab Reports page.
Conclusion
Semax has produced measurable changes in neurotrophic and stress-response pathways in experimental cerebral ischemia. Rat studies have described changes in BDNF-, NGF-, CREB-, MMP-9- and JNK-related signalling. A smaller human rehabilitation study reported higher circulating BDNF and favourable functional associations.
Together, these findings support continued investigation of Semax in neurological research. They do not yet establish reliable cognitive enhancement in healthy adults or broadly effective treatment of human neurological disease.
Frequently Asked Questions
What is Semax peptide?
Semax is a synthetic seven-amino-acid peptide derived from the ACTH(4–7) fragment and extended with Pro-Gly-Pro.
Does Semax increase BDNF?
Rat studies have reported changes in Bdnf transcription. A small human stroke-rehabilitation study reported higher plasma BDNF, which is not the same as measuring BDNF signalling in the brain.
Does Semax improve memory?
Reliable improvements in healthy adult memory have not been established by large, independently replicated clinical trials.
Does Semax help with stroke recovery?
A small human study reported favourable rehabilitation findings. More rigorous trials are needed to establish clinical effectiveness.
Does Semax affect NGF?
Rat studies have shown changes in Ngf transcription following experimental cerebral ischemia. The clinical importance of those findings remains uncertain.
How is Semax different from Selank?
Semax is ACTH-derived and has been studied mainly in neurotrophic and ischemia models. Selank is tuftsin-derived and has been investigated more in anxiety-related neurotransmission.
Is Semax approved in Canada?
No. Semax is not authorized by Health Canada for neurological treatment or cognitive enhancement.
Scientific References
1. Dmitrieva VG, et al. (2010; online 2009). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology. DOI: 10.1007/s10571-009-9432-0. PubMed record.
2. Sudarkina OYu, et al. (2021). Brain Protein Expression Profile Confirms the Protective Effect of the ACTH(4–7)PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. International Journal of Molecular Sciences. DOI: 10.3390/ijms22126179. PubMed record.
3. Gusev EI, et al. (2018). The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii. DOI: 10.17116/jnevro20181183261-68. PubMed record.
4. Health Canada (2025). Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. Official advisory.
Explore the Kelden Research Hub for related peptide and neuroscience research, including peptides investigated in migraine research and guidance on how to interpret human versus animal studies.